AbbVie Inc. $ABBV Stock Acquired by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC grew its position in shares of AbbVie Inc. (NYSE:ABBV) by 14.4% during the third quarter, according to its most recent filing with the SEC. The firm owned 203,038 shares of the company’s stock after acquiring an additional 25,609 shares during the period. AbbVie comprises about 4.9% of Marble Harbor Investment Counsel LLC’s holdings, making the stock its 3rd largest holding. Marble Harbor Investment Counsel LLC’s holdings in AbbVie were worth $51,055,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Ranch Capital Advisors Inc. lifted its position in AbbVie by 37.0% during the 1st quarter. Ranch Capital Advisors Inc. now owns 14,888 shares of the company’s stock valued at $3,238,000 after acquiring an additional 4,017 shares during the period. Capital Advisors Inc. OK boosted its stake in AbbVie by 11.2% during the second quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock worth $112,516,000 after acquiring an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab bought a new stake in AbbVie during the second quarter worth about $23,557,000. State Street Corp grew its holdings in AbbVie by 1.7% in the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after purchasing an additional 1,379,232 shares during the period. Finally, Wedge Capital Management L L P NC grew its holdings in AbbVie by 7.5% in the second quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after purchasing an additional 9,380 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on ABBV shares. Sanford C. Bernstein reaffirmed a “market perform” rating and set a $275.00 target price on shares of AbbVie in a research note on Monday, November 2nd. JPMorgan Chase & Co. boosted their price target on AbbVie from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Thursday, October 8th. Barclays upped their price target on AbbVie from $300.00 to $325.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 21st. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and raised their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Finally, Morgan Stanley lifted their price objective on AbbVie from $310.00 to $346.00 and gave the company an “overweight” rating in a research note on Monday, November 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $297.46.

Key Stories Impacting AbbVie

Investors following ABBV have been watching these stories:

• Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
• Neutral Sentiment: AbbVie’s licensing agreement with Nxera Pharma for an inflammatory bowel disease program adds a potential pipeline opportunity, but requires AbbVie to make an upfront payment and could involve substantial milestone payments. The deal’s longer-term value depends on development and commercial success. AbbVie Deal Altering the Investment Case for Nxera Pharma?
• Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

Insider Activity

In other news, EVP Jeffrey Stewart sold 40,619 shares of the firm’s stock in a transaction dated Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president owned 83,171 shares of the company’s stock, valued at $24,419,005.60. This trade represents a 32.81% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

AbbVie Price Performance

ABBV stock opened at $294.75 on Friday. The stock has a market capitalization of $521.01 billion, a P/E ratio of 50.73, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $302.93. The business has a fifty day moving average price of $274.82 and a 200-day moving average price of $240.55.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The company had revenue of $17.40 billion for the quarter, compared to analysts’ expectations of $17.32 billion. During the same period last year, the firm posted $1.86 earnings per share. AbbVie’s revenue was up 10.3% compared to the same quarter last year. As a group, analysts anticipate that AbbVie Inc. will post 13.98 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be paid a dividend of $1.82 per share. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio (DPR) is currently 119.10%.

About AbbVie

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.